Research
Hormonal
GLP-1 receptor agonists (exendin-4 and liraglutide) improve memory deficits, reduce amyloid plaque load, and restore insulin signaling in Alzheimer's disease models.
GLP-1 drugs like liraglutide and exendin-4 show promise in animal studies for protecting the brain and improving memory in Alzheimer's. They work by activating pathways similar to insulin. While human trials are ongoing, these drugs might be a future treatment option for AD, especially if you have diabetes.
ModerateSupportsMEDIUM confidence
Exendin-4 acted decreasing the inhibitory phosphorylation of Ser312IRS1, Ser636IRS1, and of JNK, while restoring activating Tyr465IRS1 phosphorylation, then counteracting insulin signaling impairment, memory deficits and diminishing amyloid plaque load in APP/PS1 transgenic AD mice... Liraglutide reduced tau phosphorylation and prevented IR reduction and synapse loss in a c-AMP dependent manner
Why this rating
Strong preclinical evidence (mice, monkeys), but human clinical trials are described as 'pilot' or 'ongoing' with mixed or limited results so far.
Source
Insulin Resistance in Alzheimer's Disease
Laís S. S. Ferreira et al. · Frontiers in Neuroscience · 2018
DOI 10.3389/fnins.2018.00830
narrative_reviewCited 220×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intranasal insulin administration improves memory and cognitive function in patients with mild cognitive impairment (MCI) and early Alzheimer's disease, particularly in non-ApoE4 carriers and women.Good
- Peripheral metabolic dysregulation (obesity, diabetes) leads to brain insulin resistance and Alzheimer's pathology through BBB permeabilization, neuroinflammation, and AGE-RAGE signaling.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →